Breaking News, Collaborations & Alliances

CRISPR Therapeutics, ProBioGen Ink In Vivo Delivery Alliance

Multi-year research collaboration focused on the development of novel in vivo delivery modalities for CRISPR/Cas9 leveraging ProBioGen’s technology

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CRISPR Therapeutics, a biopharmaceutical company focused on creating gene-based medicines for serious diseases, and ProBioGen, a German service and technology provider, have entered a multi-year research collaboration focused on the development of novel in vivo delivery modalities for CRISPR/Cas9 leveraging ProBioGen’s existing technology and expertise. Technical and financial details of the collaboration were not disclosed. The collaboration includes a license option for CRISPR Therapeutics ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters